Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017638 (glioma)
 30,880 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

IGF-I antisense gene therapy has been applied successfully to animal models of glioma, hepatoma and teratocarcinoma. The antisense strategy has shown that tumor cells transfected with vectors encoding IGF-I antisense RNA lose tumorigenicity, become immunogenic and are associated with tumor specific immune response involving CD8+ lymphocytes. An IGF-I triple helix approach to gene therapy for glioma was recently described. The approach we have taken is to establish parameters of change using the IGF-I triple helix strategy. PCC-3 embryonal carcinoma cells derived from murine teratocarcinoma which express IGF-I were used as a model. The cells were transfected with vector which encodes an oligoribonucleotide that forms RNA-IGF-I DNA triple-helix structure. The triple-helix stops the production of IGF-I. Cells transfected in this manner underwent changes in phenotype and an increase in MHC-I and B-7 cell surface molecules. They also showed enhancement in the production of apoptotic cells (60-70%). The "triple helix" transfected cells lost the ability to induce tumor when injected subcutaneously in syngeneic 129 Sv mice. When co-transfected in vitro with expression vectors encoding both MHC-I and B-7 cDNA in antisense orientation, the "triple-helix" transfected cells were down-regulated in expression of MHC-I and B-7 and the number of apoptotic cells was significantly decreased. Injection of the doubly co-transfected cells into 129 Sv mice was associated with induction of teratocarcinoma. Comparison between antisense and triple-helix transfected cells strategies showed similar immunogenic and apoptotic changes. The findings suggest that triple-helix technology may offer a new clinical approach to treatement of tumors expressing IGF-I.
 ...
PMID:Alterations in tumorigenicity of embryonal carcinoma cells by IGF-I triple-helix induced changes in immunogenicity and apoptosis. 1119 46

Choroid plexus papilloma (CCP) is an uncommon benign neoplasm of the neuroectoderm. We present the 18F-fluoro-2-deoxy-D-glucose (FDG) and 11C-methyl-L-methionine (methionine) positron emission tomography of CPP in comparison with that of low-grade glioma. Patients were two women and one man (20, 23, and 72 years old). The Ki-67 labeling index ranged from 0.98 to 2.22%, and histologically the cases belonged to grade 2. On quantitative analysis, the tumor/normal ratio (T/N) was calculated using the standardized uptake value. Methionine T/N was significantly higher in CPP (3.24+/-0.69) than in low-grade glioma (1.23+/-0.81; p<0.01), although no clear difference could be determined for FDG T/N between the two (0.87+/-0.39, 0.75+/-0.53). These results may suggest that the metabolism of amino acid in CPP is quite different from that in low-grade glioma.
 ...
PMID:18F-FDG and 11C-methionine PET in choroid plexus papilloma--report of three cases. 1204 6